BioTech News and Headlines

Gene Therapies for Hearing Loss Strike an Encouraging Note in Embattled Modality
NewsMar 23, 2026

Gene Therapies for Hearing Loss Strike an Encouraging Note in Embattled Modality

Gene‑therapy candidates for hereditary hearing loss are gaining traction as safety concerns ease with localized delivery. Regeneron’s DB‑OTO and Eli Lilly’s AK‑OTOF have each demonstrated clinically meaningful hearing improvements in early‑stage trials, positioning them as frontrunners for the first approved deafness...

By BioSpace
9 Months In, FDA’s New Priority Voucher Program Still Clouded With Uncertainty
NewsMar 23, 2026

9 Months In, FDA’s New Priority Voucher Program Still Clouded With Uncertainty

The FDA’s National Priority Voucher (CNPV) program, launched in June 2025, promises to cut drug review times from 10‑12 months to just one or two months for products that meet defined national priorities. Early successes include Johnson & Johnson’s Tecvayli/Darzalex...

By BioSpace
NADPH Oxidase-1 Suppression Prolongs the Antidepressant-Like Effect of Ketamine
NewsMar 23, 2026

NADPH Oxidase-1 Suppression Prolongs the Antidepressant-Like Effect of Ketamine

Researchers introduced K‑4, a novel AMPA‑receptor positive allosteric modulator, which produced rapid and sustained antidepressant‑like effects in treatment‑resistant depression rat models. Bulk RNA‑seq revealed that K‑4 markedly down‑regulated NADPH oxidase‑1 (NOX‑1) in the medial prefrontal cortex and lateral habenula. Pharmacological...

By Nature (Biotechnology)
J. Michael Bishop, Nobel Prize Winner for Cancer Research, Dies at 90
NewsMar 22, 2026

J. Michael Bishop, Nobel Prize Winner for Cancer Research, Dies at 90

J. Michael Bishop, Nobel laureate who uncovered oncogenes, died at 90 from pneumonia. His 1989 Nobel Prize with Harold Varmus identified gene families that mutate into cancer‑causing oncogenes, fundamentally altering tumor biology. Bishop joined UCSF in 1968, later serving as...

By New York Times – Science
FDA Drug Safety Communication: Revised Recommendations for Celexa (Citalopram Hydrobromide) Related to a Potential Risk of Abnormal Heart Rhythms with...
NewsMar 22, 2026

FDA Drug Safety Communication: Revised Recommendations for Celexa (Citalopram Hydrobromide) Related to a Potential Risk of Abnormal Heart Rhythms with...

The FDA issued a Drug Safety Communication clarifying that citalopram (Celexa) should not be prescribed above 40 mg daily because higher doses significantly prolong the QT interval and can trigger fatal Torsade de Pointes. The label now mandates a maximum of...

By FDA
FDA Drug Safety Communication: Updated Information About the Risk of Blood Clots in Women Taking Birth Control Pills Containing Drospirenone
NewsMar 22, 2026

FDA Drug Safety Communication: Updated Information About the Risk of Blood Clots in Women Taking Birth Control Pills Containing Drospirenone

The FDA has updated labels for drospirenone‑containing oral contraceptives after reviewing epidemiologic studies that suggest a potentially higher risk of venous thromboembolism compared with other progestins. The new warnings note that some studies report up to a three‑fold increase in...

By FDA
FDA Drug Safety Communication: New Warning and Contraindication for Blood Pressure Medicines Containing Aliskiren (Tekturna)
NewsMar 22, 2026

FDA Drug Safety Communication: New Warning and Contraindication for Blood Pressure Medicines Containing Aliskiren (Tekturna)

The FDA issued a drug safety communication on April 20, 2012, adding a contraindication for aliskiren‑containing antihypertensives when combined with ACE inhibitors or ARBs in patients with diabetes, and a warning for those with moderate to severe renal impairment. The...

By FDA
FDA Drug Safety Communication: Updated Information on Drug Interactions Between Victrelis (Boceprevir) and Certain Boosted HIV Protease Inhibitor Drugs
NewsMar 22, 2026

FDA Drug Safety Communication: Updated Information on Drug Interactions Between Victrelis (Boceprevir) and Certain Boosted HIV Protease Inhibitor Drugs

The FDA issued an updated Drug Safety Communication warning that co‑administration of Victrelis (boceprevir) with ritonavir‑boosted HIV protease inhibitors—atazanavir, darunavir, or lopinavir/ritonavir—is not recommended for patients co‑infected with hepatitis C and HIV. The interaction lowers blood concentrations of both drugs,...

By FDA
FDA Drug Safety Communication: Safety Review Update of Cancer Drug Revlimid (Lenalidomide) and Risk of Developing New Types of Malignancies
NewsMar 22, 2026

FDA Drug Safety Communication: Safety Review Update of Cancer Drug Revlimid (Lenalidomide) and Risk of Developing New Types of Malignancies

The FDA added a safety warning to Revlimid (lenalidomide) after clinical trials showed a markedly higher incidence of second primary malignancies in newly diagnosed multiple myeloma patients. Pooled data revealed a three‑fold increase (7.9% vs 2.8%) in cancers such as...

By FDA
FDA Drug Safety Communication: Cefepime and Risk of Seizure in Patients Not Receiving Dosage Adjustments for Kidney Impairment
NewsMar 22, 2026

FDA Drug Safety Communication: Cefepime and Risk of Seizure in Patients Not Receiving Dosage Adjustments for Kidney Impairment

The FDA issued a Drug Safety Communication reminding clinicians to adjust cefepime doses for patients with creatinine clearance ≤ 60 mL/min. Non‑convulsive status epilepticus has been linked to inappropriate dosing, with 59 reported cases since 1996, 58 of which involved renal dysfunction...

By FDA
FDA Drug Safety Communication: Seizure Risk for Multiple Sclerosis Patients Who Take Ampyra (Dalfampridine)
NewsMar 22, 2026

FDA Drug Safety Communication: Seizure Risk for Multiple Sclerosis Patients Who Take Ampyra (Dalfampridine)

The FDA issued a Drug Safety Communication warning that dalfampridine (Ampyra), approved to improve walking in multiple sclerosis patients, carries a significant seizure risk, especially shortly after therapy initiation. Post‑marketing data show most seizures occur within days‑to‑weeks and in patients...

By FDA
FDA Drug Safety Communication: FDA Recommends Against Use of Revatio (Sildenafil) in Children with Pulmonary Hypertension
NewsMar 22, 2026

FDA Drug Safety Communication: FDA Recommends Against Use of Revatio (Sildenafil) in Children with Pulmonary Hypertension

The FDA issued a drug safety communication recommending that Revatio (sildenafil) not be prescribed to children aged 1‑17 for pulmonary arterial hypertension. A long‑term pediatric trial of 234 patients showed no exercise benefit and a three‑fold increase in mortality at...

By FDA
Competitive ELISA Explained: Mechanism, Data Interpretation, and Research Applications
NewsMar 22, 2026

Competitive ELISA Explained: Mechanism, Data Interpretation, and Research Applications

Competitive ELISA is a plate‑based assay where an enzyme‑labeled antigen competes with sample antigen for a limited antibody binding site, producing an inverse signal. As target concentration rises, the measured colorimetric signal falls, generating a descending standard curve. The format...

By Healthcare Guys
Genetic Study Finds Links Between Height and Risk of Cardiovascular and Reproductive Conditions in East Asian People
NewsMar 22, 2026

Genetic Study Finds Links Between Height and Risk of Cardiovascular and Reproductive Conditions in East Asian People

A large‑scale GWAS of over 120,000 Han Taiwanese participants identified 293 genetic variants linked to height and five linked to familial short stature. The study found that greater genetically‑predicted height raises the risk of atrial fibrillation and endometriosis in East...

By Medical Xpress
Could Ozempic Help People Whose Cancer Has Spread to the Brain?
NewsMar 22, 2026

Could Ozempic Help People Whose Cancer Has Spread to the Brain?

A large retrospective analysis of over 19,000 patients with cancer, type 2 diabetes and brain metastases found that those prescribed GLP‑1 receptor agonists such as Ozempic or Wegovy experienced a 37% reduction in three‑year mortality compared with matched controls. The survival...

By Medical Xpress
Lab-Grown Brain Models Reveal Unique Electrical Patterns in Different Types of Autism
NewsMar 22, 2026

Lab-Grown Brain Models Reveal Unique Electrical Patterns in Different Types of Autism

Researchers created patient‑derived brain organoids from urine cells and recorded their electrical activity, revealing distinct electrophysiological signatures for neurotypical controls, syndromic autism, and idiopathic autism. Organoids from syndromic cases showed hyper‑activity, while the idiopathic sample displayed reduced firing rates. Principal...

By PsyPost
The Deep Cave Bacteria Defying Modern Medicine
NewsMar 22, 2026

The Deep Cave Bacteria Defying Modern Medicine

Scientists exploring the isolated Lechuguilla Cave discovered microbial communities that are resistant to virtually all natural antibiotics, despite being sealed off for millions of years. Genomic analysis of a *Paenibacillus* strain revealed dozens of known resistance genes and five entirely...

By BBC Future
Kyoto Medical Firm to Launch Personal iPS Cell Storage Service
NewsMar 22, 2026

Kyoto Medical Firm to Launch Personal iPS Cell Storage Service

Kyoto-based iPS Portal Inc. will launch a personal induced pluripotent stem cell storage service in April, allowing individuals to generate iPS cells from their own blood for future clinical use. The service, developed with pharmaceutical experts, will cost between 10 million...

By Kyodo News – English (All)
UK Study Reveals No Additional Advantage of Surfactant Therapy in Severe Bronchiolitis Cases in Infants
NewsMar 22, 2026

UK Study Reveals No Additional Advantage of Surfactant Therapy in Severe Bronchiolitis Cases in Infants

UK researchers completed the largest randomized trial evaluating exogenous surfactant in infants with severe bronchiolitis requiring mechanical ventilation. The Bronchiolitis Endotracheal Surfactant Study (BESS) enrolled 232 infants across 15 pediatric centers and found that surfactant administration did not shorten ventilation...

By Bioengineer.org
Psychedelic Drug MDMA Could Help Treat PTSD—But There's a Reason It's Not Widely Available
NewsMar 22, 2026

Psychedelic Drug MDMA Could Help Treat PTSD—But There's a Reason It's Not Widely Available

Australia became the first nation to reclassify MDMA from a prohibited to a controlled substance, permitting its use in PTSD treatment under strict conditions. The 2026 guidelines limit MDMA‑assisted psychotherapy to adults who have not responded to first‑line therapies, require...

By Medical Xpress
El Plan De Ignacio Del Río Goudie Para Polinizar Estados Unidos
NewsMar 21, 2026

El Plan De Ignacio Del Río Goudie Para Polinizar Estados Unidos

Chilean agritech startup Biopollen, spun off from Ignacio del Río Goudie's holding, commercializes a liquid‑pollen technology that boosts fruit set in low‑pollination crops. The method harvests fresh pollen, keeps it viable in a chilled liquid, and sprays it aerially with...

By Diario Financiero
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026
NewsMar 21, 2026

Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026

Prothena and its partners presented new clinical data on prasinezumab for Parkinson’s disease and BMS‑986446 for Alzheimer’s disease at the AD/PD 2026 conference in Copenhagen. The PASADENA and PADOVA extensions suggest a two‑year disease‑progression delay and sustained biomarker effects, supporting the...

By Digital Health Global
Light-Based Technique Creates Artificial Structures that Mimic the Scaffolding of Cells
NewsMar 21, 2026

Light-Based Technique Creates Artificial Structures that Mimic the Scaffolding of Cells

Researchers at RIKEN have introduced a laser‑based optogenetic system that prints three‑dimensional actin networks directly onto lipid bilayers, effectively acting as a 3‑D printer for cytoskeletal scaffolds. By adjusting light intensity, pulse length, and pattern, they can independently control network...

By Phys.org – Biotechnology
Blood Test Predicts Long-Term Cognitive Function After Cardiac Arrest
NewsMar 21, 2026

Blood Test Predicts Long-Term Cognitive Function After Cardiac Arrest

A study presented at the ESC Acute Cardiovascular Care 2026 congress found that neurofilament light chain (NfL) measured 48 hours after out‑of‑hospital cardiac arrest reliably predicts long‑term cognitive function. Compared with the traditional biomarker neuron‑specific enolase (NSE), NfL showed a strong...

By Neuroscience News
Metformin vs Dapagliflozin: Heart Protection in Diabetic Rats
NewsMar 21, 2026

Metformin vs Dapagliflozin: Heart Protection in Diabetic Rats

Researchers compared metformin and dapagliflozin in diabetic rats subjected to myocardial infarction, finding dapagliflozin delivered stronger cardio‑protective effects. The SGLT2 inhibitor markedly reduced oxidative stress, inflammatory cytokines, and infarct size, while also improving calcium handling and contractile efficiency. Metformin showed...

By Bioengineer.org
Juicier Steaks Soon? The UK Approves Testing of Gene-Edited Cow Feed
NewsMar 21, 2026

Juicier Steaks Soon? The UK Approves Testing of Gene-Edited Cow Feed

British regulators have approved the first gene‑edited crop for animal feed, allowing Golden Promise barley with increased fat content to be tested on cattle. The modified barley is designed to accelerate weight gain, boost milk production and cut methane emissions...

By Slashdot
How DICER Cuts microRNAs with Single-Nucleotide Precision
NewsMar 21, 2026

How DICER Cuts microRNAs with Single-Nucleotide Precision

HKUST researchers have uncovered how human DICER achieves single‑nucleotide precision when cleaving microRNA precursors. Using high‑resolution cryo‑EM, they visualized DICER’s interaction with RNA and identified two distinct 5′‑end binding pockets—one favoring uridine and a newly discovered pocket favoring guanosine. The...

By Phys.org – Biotechnology
Noteworthy Studies on JAK Inhibitors, Skin-Gut Relationship in Alopecia Areata: Maria Hordinsky, MD
NewsMar 21, 2026

Noteworthy Studies on JAK Inhibitors, Skin-Gut Relationship in Alopecia Areata: Maria Hordinsky, MD

Maria Hordinsky, MD highlighted the rapid evolution of alopecia areata therapy, noting three FDA‑approved Janus kinase (JAK) inhibitors launched in the last five years. She discussed the efficacy of agents such as dupilumab and baricitinib, while emphasizing emerging research on...

By AJMC (The American Journal of Managed Care)
Glenmark Launches GLIPIQ for Type 2 Diabetes in India
NewsMar 21, 2026

Glenmark Launches GLIPIQ for Type 2 Diabetes in India

Glenmark Pharmaceuticals has launched GLIPIQ, a semaglutide‑based GLP‑1 therapy, in India following CDSCO approval after a local Phase III study. The product is offered in both vial‑with dose‑specific syringes and pre‑filled pen formats, covering 2 mg, 4 mg and 8 mg strengths. Pricing is...

By afaqs! (India)
Study Finds FGFR1 Boosts Cholesterol Uptake in Prostate Cancer Cells
NewsMar 21, 2026

Study Finds FGFR1 Boosts Cholesterol Uptake in Prostate Cancer Cells

Researchers at Texas A&M Health discovered that the fibroblast growth factor receptor 1 (FGFR1) drives cholesterol accumulation in prostate cancer cells by activating the sterol regulatory element‑binding protein 2 (SREBP2). This signaling cascade up‑regulates LDL‑receptor (LDLR) and cholesterol‑synthesis enzymes, boosting intracellular cholesterol...

By Medical Xpress
Aelis Farma Announces the Successful Start of the Recruitment of the Phase 2B Clinical Trial with AEF0217 for the Treatment...
NewsMar 21, 2026

Aelis Farma Announces the Successful Start of the Recruitment of the Phase 2B Clinical Trial with AEF0217 for the Treatment...

Aelis Farma announced that recruitment has begun for its Phase 2B trial of AEF0217, a first‑in‑class signalling‑specific CB1 receptor inhibitor, aimed at treating behavioral and cognitive impairments in Down syndrome. The study will enroll 188 participants aged 16‑32 across ten...

By Euronext
What Is Flumist, the New Flu Vaccine for Kids That's Sprayed in Their Noses?
NewsMar 21, 2026

What Is Flumist, the New Flu Vaccine for Kids That's Sprayed in Their Noses?

Australia will introduce FluMist, a needle‑free nasal flu vaccine for children aged 2‑17, this winter. The live‑attenuated spray targets the upper respiratory tract and offers protection comparable to injectable shots, reducing flu cases by 40‑60%. It will be free for...

By Medical Xpress
Comprehensive Single-Cell Transcriptomic Atlas of Microglia in Alzheimer’s Disease Mouse Models
NewsMar 21, 2026

Comprehensive Single-Cell Transcriptomic Atlas of Microglia in Alzheimer’s Disease Mouse Models

A new study delivers a comprehensive single‑cell transcriptomic atlas of microglia from multiple Alzheimer’s disease mouse models. By profiling thousands of cells, researchers uncovered diverse microglial states, including disease‑associated subtypes linked to TREM2 signaling and amyloid pathology. The atlas integrates...

By Nature (Biotechnology)
LINC01116 Binds CPS1 to Regulate Urea Cycle Function, Thereby Promoting Progression and Chemoresistance in Osteosarcoma
NewsMar 20, 2026

LINC01116 Binds CPS1 to Regulate Urea Cycle Function, Thereby Promoting Progression and Chemoresistance in Osteosarcoma

The study reveals that the long non‑coding RNA LINC01116 is markedly up‑regulated in metastatic osteosarcoma and directly binds the urea‑cycle enzyme CPS1. Disruption of the LINC01116‑CPS1 interaction impairs citrulline production, indicating a compromised urea cycle, and markedly suppresses tumor proliferation...

By Research Square – News/Updates
FDA Drug Safety Communication: Planned Return of CardioGen-82 to Market with New Boxed Warning
NewsMar 20, 2026

FDA Drug Safety Communication: Planned Return of CardioGen-82 to Market with New Boxed Warning

On February 15, 2012, the FDA announced that Bracco Diagnostics’ CardioGen‑82 generator will re-enter the U.S. market after a voluntary recall in July 2011. The agency approved revised labeling that introduces a Boxed Warning and new “Alert Limits” for strontium‑82...

By FDA
FDA Drug Safety Communication: Safety Update on Progressive Multifocal Leukoencephalopathy (PML) Associated with Tysabri (Natalizumab)
NewsMar 20, 2026

FDA Drug Safety Communication: Safety Update on Progressive Multifocal Leukoencephalopathy (PML) Associated with Tysabri (Natalizumab)

The FDA has revised the Tysabri (natalizumab) label to detail progressive multifocal leukoencephalopathy (PML) risk based on infusion count and prior immunosuppressant exposure. Data show 102 PML cases among 82,732 treated patients, with incidence rising sharply after 24 infusions. A...

By FDA
'Meaningful' FDA Clearance Opens New Osteoarthritis Treatment Pathway
NewsMar 20, 2026

'Meaningful' FDA Clearance Opens New Osteoarthritis Treatment Pathway

The FDA has granted clearance for Siemens Healthineers’ Varian radiotherapy platforms—including TrueBeam, TrueBeam STx, VitalBeam and Edge—to treat medically refractory osteoarthritis in adults. Low‑dose radiation therapy offers a non‑invasive alternative to steroid injections, physical therapy, and ultimately joint replacement surgery...

By Radiology Business
Letrozole vs GnRH Antagonist in Ovarian Aging IVF
NewsMar 20, 2026

Letrozole vs GnRH Antagonist in Ovarian Aging IVF

A recent multicenter trial compared letrozole‑based protocols with traditional GnRH antagonist regimens for women experiencing ovarian aging undergoing IVF. The study found that letrozole reduced total gonadotropin dose and improved mature oocyte yield without compromising clinical pregnancy rates. GnRH antagonists...

By Bioengineer.org
EyePoint Sues Rival Ocular Therapeutix, Alleging False Claims About Eye Drug
NewsMar 20, 2026

EyePoint Sues Rival Ocular Therapeutix, Alleging False Claims About Eye Drug

EyePoint Therapeutics filed a lawsuit in Massachusetts accusing rival Ocular Therapeutix of spreading false and misleading statements about EyePoint’s lead experimental eye drug, Duravyu. The complaint alleges defamation, commercial disparagement, consumer‑protection violations, and interference with business relationships. EyePoint seeks a...

By PharmaLive
Chemo-Optogenetic Tool Uses Vitamin B₁₂ and Green Light to Precisely Regulate Cell Communication
NewsMar 20, 2026

Chemo-Optogenetic Tool Uses Vitamin B₁₂ and Green Light to Precisely Regulate Cell Communication

Researchers at HKUST have created CarGAP, a chemo‑optogenetic system that couples vitamin B₁₂ binding with green‑light activation to toggle gap junctions on and off. In the dark, vitamin B₁₂ induces oligomerization of a bacterial CarHC domain, physically blocking connexin or innexin channels;...

By Phys.org – Biotechnology
LazySlide: Open Framework for Integrating Whole-Slide and Molecular Data
NewsMar 20, 2026

LazySlide: Open Framework for Integrating Whole-Slide and Molecular Data

LazySlide is an open‑source Python package built on the scverse ecosystem that streamlines whole‑slide image analysis and multimodal integration. It partitions massive pathology slides into manageable patches, applies foundation AI models to extract visual features, and directly links those features...

By GEN (Genetic Engineering & Biotechnology News)
Scientists Bring Mouse Brains Back to Life After “Cryosleep” Deep Freeze
NewsMar 20, 2026

Scientists Bring Mouse Brains Back to Life After “Cryosleep” Deep Freeze

Researchers at the University of Erlangen‑Nuremberg successfully revived neuronal activity in vitrified mouse brain slices after cryogenic storage. Using rapid cooling to –320 °F, they preserved synaptic membranes and long‑term potentiation for up to seven days. Electrical testing showed largely normal...

By Futurism BioTech
Targeting Tunneling Nanotubes Reduces Spread of Mutant Huntington’s Protein
NewsMar 20, 2026

Targeting Tunneling Nanotubes Reduces Spread of Mutant Huntington’s Protein

Researchers at Florida Atlantic University discovered that the protein Rhes teams up with the bicarbonate transporter SLC4A7 to build tunneling nanotubes (TNTs) that ferry mutant huntingtin (mHTT) between neurons. Disrupting this Rhes‑SLC4A7 axis in mice dramatically curbed intercellular spread of...

By GEN (Genetic Engineering & Biotechnology News)
FDA Approves Nivolumab Regimen as First-Line Treatment for Classical Hodgkin Lymphoma
NewsMar 20, 2026

FDA Approves Nivolumab Regimen as First-Line Treatment for Classical Hodgkin Lymphoma

The FDA has granted first‑line approval for a nivolumab‑plus‑AVD regimen in patients aged 12 and older with stage III‑IV classical Hodgkin lymphoma. The decision follows the phase 3 SWOG S1826 trial, which showed a 58% progression‑free survival rate and a hazard ratio of...

By Healio
Higher-Dose Semaglutide Approved Under New FDA Accelerated Review Process
NewsMar 20, 2026

Higher-Dose Semaglutide Approved Under New FDA Accelerated Review Process

The FDA granted accelerated approval to Wegovy HD, a 7.2 mg weekly semaglutide injection, marking the fourth product cleared under the National Priority Voucher pilot. Phase 3 STEP UP data showed a mean 20.7% weight loss, with nearly one‑third of participants shedding 25% or...

By AJMC (The American Journal of Managed Care)
ICAR–IVRI Achieves Breakthrough in Sahiwal Breeding Using Advanced Reproductive Technologies
NewsMar 20, 2026

ICAR–IVRI Achieves Breakthrough in Sahiwal Breeding Using Advanced Reproductive Technologies

The Indian Council of Agricultural Research’s Veterinary Research Institute (ICAR‑IVRI) has produced the first indigenous Sahiwal calves using ultrasound‑guided ovum pick‑up, in‑vitro fertilisation and embryo transfer (OPU‑IVF‑ET). Within five days in February‑March 2026, five healthy calves were born from a...

By The Economic Times (India) – Economy
Early Use of Tirzepatide After Heart Attack or Stroke Linked to Key Cardiovascular Benefits
NewsMar 20, 2026

Early Use of Tirzepatide After Heart Attack or Stroke Linked to Key Cardiovascular Benefits

A real‑world propensity‑matched study of 1,666 non‑diabetic patients found that initiating tirzepatide within 14 days of an acute myocardial infarction or ischemic stroke cut the risk of emergency‑room visits, hospitalizations, acute kidney injury, repeat stroke and heart‑failure admission over two...

By Cardiovascular Business
Major Leap Towards Reanimation After Death as Mammal's Brain Preserved
NewsMar 20, 2026

Major Leap Towards Reanimation After Death as Mammal's Brain Preserved

Researchers at Nectome have successfully cryopreserved an entire pig brain, locking cellular activity with minimal damage. The method uses rapid vitrification to prevent ice formation, preserving neural architecture and synaptic connections. Nectome now plans to offer the service to terminally...

By New Scientist – Robots
Understanding Public Perspectives on Direct to Consumer Pharmacogenomic Testing in the UK: A Qualitative Study
NewsMar 20, 2026

Understanding Public Perspectives on Direct to Consumer Pharmacogenomic Testing in the UK: A Qualitative Study

Direct‑to‑consumer pharmacogenomic testing is rapidly expanding in the UK despite the absence of a dedicated regulatory framework. A 2021 parliamentary inquiry called for stronger safeguards, but these have not been applied to PGx services. Researchers conducted focus groups with consumers...

By Research Square – News/Updates